{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:54:54Z","timestamp":1792130094443,"version":"4.4.0"},"reference-count":20,"publisher":"Massachusetts Medical Society","issue":"10","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2024,3,7]]},"DOI":"10.1056\/nejmoa2312117","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T17:01:12Z","timestamp":1709744472000},"page":"875-888","source":"Crossref","is-referenced-by-count":1138,"title":["Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer"],"prefix":"10.1056","volume":"390","author":[{"given":"Thomas","family":"Powles","sequence":"first","affiliation":[{"name":"Saint Barts Cancer Centre, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Rocio, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[{"name":"Klinikum Stuttgart Katharinen Hospital, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-5660","authenticated-orcid":false,"given":"Christof","family":"Vulsteke","sequence":"additional","affiliation":[{"name":"Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, Belgium and Center for Oncological Research, Antwerp University, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Shin","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ri","family":"Li","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[{"name":"Istanbul Medeniyet University Goztepe Training and Research, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Mar","sequence":"additional","affiliation":[{"name":"University of California, Irvine Medical Center, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[{"name":"Centre Leon Berard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Seagen Inc., Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Yu","sequence":"additional","affiliation":[{"name":"Seagen Inc., Bothell, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Gorla","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Homet Moreno","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","volume-title":"SEER cancer stat facts: bladder cancer","year":"2023","unstructured":"SEER cancer stat facts: bladder cancer. Bethesda, MD: National Cancer Institute, 2023."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S409791"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4508"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2"},{"key":"e_1_3_5_13_2","first-page":"A1231","article-title":"Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors.","volume":"10","author":"Olson D","year":"2022","unstructured":"Olson D, Younan P, Liu B, et al. Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors. J Immunother Cancer 2022;10:Suppl 2:A1231-A1231. abstract.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.012"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.466"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.572"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.483"},{"key":"e_1_3_5_21_2","first-page":"S20","article-title":"Real-world avelumab maintenance eligibility and treatment patterns in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.","volume":"29","author":"Morgans A","year":"2023","unstructured":"Morgans A, Powles T, Shih V, et al. Real-world avelumab maintenance eligibility and treatment patterns in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. J Manag Care Spec Pharm 2023;29:Suppl:S20-S21. abstract.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2312117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T18:51:24Z","timestamp":1754074284000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2312117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,3,7]]}},"alternative-id":["10.1056\/NEJMoa2312117"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2312117","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}